This hypothesis proposes using C1q complement protein as a delivery vehicle for miR-33 antisense oligonucleotides to achieve targeted brain penetration and APOE4 hyper-lipidation in Alzheimer's disease. C1q naturally crosses the blood-brain barrier via receptor-mediated transcytosis through C1qR and gC1qR receptors highly expressed on brain endothelial cells. By conjugating miR-33 ASOs to C1q, we can leverage this endogenous transport mechanism to deliver therapeutic oligonucleotides directly to
This hypothesis combines targeted miR-33 inhibition with complement-mediated brain delivery to overcome APOE4's inherent lipidation deficiency in Alzheimer's disease. The strategy involves conjugating miR-33 antisense oligonucleotides (ASOs) to C1q complement protein to achieve receptor-mediated transcytosis across the blood-brain barrier. C1q naturally crosses the BBB via complement receptor-mediated endocytosis and accumulates in microglial cells, the primary brain cell type expressing ABCA1.
Verdict Summary
5/10
dimensions won
C1q-Conjugated miR-33 ASO Brain Delivery
5/10
dimensions won
C1q-Mediated Delivery of miR-33 Antisens
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.76
0.70
Evidence
0.00
0.36
Novelty
0.40
0.00
Feasibility
0.37
0.00
Impact
0.41
0.00
Druggability
0.50
0.55
Safety
0.47
0.45
Competition
0.45
0.50
Data
0.40
0.70
Reproducible
0.58
0.65
Score Breakdown
Dimension
C1q-Conjugated miR-33 ASO Brai
C1q-Mediated Delivery of miR-3
Mechanistic
0.760
0.700
Evidence
0.000
0.360
Novelty
0.400
0.000
Feasibility
0.370
0.000
Impact
0.410
0.000
Druggability
0.500
0.550
Safety
0.470
0.450
Competition
0.450
0.500
Data
0.400
0.700
Reproducible
0.580
0.650
Evidence
C1q-Conjugated miR-33 ASO Brain Delivery for Enhanced APOE4
No evidence citations yet
C1q-Mediated Delivery of miR-33 Antisense Oligonucleotides f
No evidence citations yet
Debate Excerpts
C1q-Conjugated miR-33 ASO Brain Delivery for Enhan